Key result
COX-2 inhibitors may promote or exacerbate a tendency to thrombosis, highlighting a need for surveillance as their widespread community use increases.
Why the study?
Does the use of COX-2 inhibitors (celecoxib, rofecoxib) increase the risk of thrombotic events in patients with chronic arthropathies?
Does the use of COX-2 inhibitors (celecoxib, rofecoxib) increase the risk of thrombotic events in patients with chronic arthropathies?
Raises awareness about the potential thrombotic risks associated with the widespread use of COX-2 inhibitors, emphasizing the need for clinical surveillance.
Answers are grounded in this paper and cite their sources.
Supports thrombotic surveillance with COX-2 inhibitors; leaves open precise risk quantification in prospective studies.
Cyclooxygenase-2 (COX-2) inhibitors belong to a new class of drugs which have anti-inflammatory efficacy similar to that of traditional non-steroidal anti-inflammatory drugs (NSAIDs), but are associated with a reduced incidence of adverse upper gastrointestinal events. Biochemical evidence that COX-2 inhibitors could promote or exacerbate a tendency to thrombosis is supported by recent results from clinical trials and case reports. Two agents in this class, celecoxib and rofecoxib, have been listed on the Pharmaceutical Benefits Scheme (PBS) for very broad indications in chronic arthropathies, suggesting that they will move into widespread community use. It is important to canvass the possibility that use of these agents could be associated with thrombotic events.
No takes yet. Share an insight, caveat, or question.
Cleland et al. (2001) conducted a review in Chronic arthropathies. COX-2 inhibitors (celecoxib and rofecoxib) vs. Traditional NSAIDs was evaluated on Thrombotic events. COX-2 inhibitors may promote or exacerbate a tendency to thrombosis, highlighting a need for surveillance as their widespread community use increases.
Synapse has enriched 10 related papers. Consider them for comparative context: